Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.63 |
| ▸ | IL17A | Q16552 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.57 |
| ▸ | BRD1 | O95696 | 1/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241241 | 0.88 | BRD4 (0.68) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL146190 | 0.87 | BRD4 (0.73) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30434520 | 0.87 | BRD4 (0.73) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL378113 | 0.87 | BRD4 (0.67) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL378522 | 0.87 | BRD4 (0.62) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30054393 | 0.86 | BRD4 (0.69) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL348541 | 0.86 | BRD4 (0.66) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL147943 | 0.86 | BRD4 (0.69) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL348295 | 0.85 | BRD4 (0.70) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL17930617 | 0.84 | BRD4 (0.74) | BRD4IL17AHDAC1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | BRD4 928/4885IL17A 4732/4885HDAC1 551/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | BRD4 2609/4885IL17A 4876/4885HDAC1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.